Suppr超能文献

壳聚糖-g-PEG 接枝纳米粒作为组织型纤溶酶原激活物给药半衰期增强载体的研究。

Investigation of chitosan-g-PEG grafted nanoparticles as a half-life enhancer carrier for tissue plasminogen activator delivery.

机构信息

Atherosclerosis Research Center, Baqiyatallah University of Medical Science, Tehran, Iran.

Department of Medical Nanotechnology, Applied Biophotonics Research Center, Science and Research Branch, Islamic Azad University, Tehran, Iran.

出版信息

IET Nanobiotechnol. 2020 Dec;14(9):899-907. doi: 10.1049/iet-nbt.2019.0304.

Abstract

Tissue plasminogen activator (tPA) a thrombolytic agent is commonly used for digesting the blood clot. tPA half-life is low (4-6 min) and its administration needs a prolonged continuous infusion. Improving tPA half-life could reduce enzyme dosage and enhance patient compliance. Nano-carries could be used as delivery systems for the protection of enzymes physically, enhancing half-life and increasing the stability of them. In this study, chitosan (CS) and polyethylene glycol (PEG) were used for the preparation of CS-g-PEG/tPA nanoparticles (NPs) via the ion gelation method. Particles' size and loading capacity were optimised by central composite design. Then, NPs cytotoxicity, release profile, enzyme activity and in vivo half-life and coagulation time were investigated. The results showed that NPs does not have significant cytotoxicity. Release study revealed that a burst effect happened in the first 5 min and resulted in releasing 30% of tPA. Loading tPA in NPs could decrease 25% of its activity but the half-life of it increases in comparison to free tPA in vivo. Also, blood coagulation time has significantly affected (-value = 0.041) by encapsulated tPA in comparison to free tPA. So, CS-g-PEG/tPA could increase enzyme half-life during the time and could be used as a non-toxic candidate delivery system for tPA.

摘要

组织型纤溶酶原激活剂(tPA)是一种常用的溶栓药物,用于分解血凝块。tPA 的半衰期较短(4-6 分钟),需要长时间持续输注。延长 tPA 的半衰期可以减少酶的用量,提高患者的依从性。纳米载体可用作酶的保护和输送系统,通过物理方式提高半衰期并增强其稳定性。在这项研究中,壳聚糖(CS)和聚乙二醇(PEG)通过离子凝胶法用于制备 CS-g-PEG/tPA 纳米颗粒(NPs)。通过中心复合设计优化了颗粒的粒径和载药量。然后,研究了 NPs 的细胞毒性、释放特性、酶活性以及体内半衰期和凝血时间。结果表明,NPs 没有明显的细胞毒性。释放研究表明,在最初的 5 分钟内会发生爆发效应,导致 30%的 tPA 释放。将 tPA 载入 NPs 中可以降低其 25%的活性,但与游离 tPA 相比,其体内半衰期会延长。此外,凝血时间也显著影响了包载 tPA 的活性(-值=0.041)。因此,CS-g-PEG/tPA 可以在延长时间内增加酶的半衰期,并且可以作为 tPA 的一种非毒性候选输送系统。

相似文献

本文引用的文献

1
Recent advances in polymeric drug delivery systems.聚合物药物递送系统的最新进展。
Biomater Res. 2020 Jun 6;24:12. doi: 10.1186/s40824-020-00190-7. eCollection 2020.
2
Engineered microparticles and nanoparticles for fibrinolysis.用于纤维蛋白溶解的工程化微球和纳米颗粒。
J Thromb Haemost. 2019 Dec;17(12):2004-2015. doi: 10.1111/jth.14637. Epub 2019 Oct 7.
8
Stroke Death Rate Plateaus.中风死亡率趋于平稳。
JAMA. 2017 Nov 14;318(18):1751. doi: 10.1001/jama.2017.15453.
9
Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.基于组织型纤溶酶原激活物的纳米溶栓治疗缺血性脑卒中。
Expert Opin Drug Deliv. 2018 Feb;15(2):173-184. doi: 10.1080/17425247.2018.1384464. Epub 2017 Sep 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验